Wells Fargo sees this biotech stock rallying 75% in its bull case
The success of one of Kymera Therapeutics’ experimental treatments could mean more upside ahead for the stock, Wells Fargo found. Analyst Derek Archila upgraded shares to overweight from equal weight and upped his price target by $19 to $57, which implies more than 21% upside from Friday’s close. Shares have already significantly outperformed the broader … Read more